{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:47:06Z","timestamp":1783986426152,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11886-019-1121-0","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T06:02:37Z","timestamp":1552888957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardiotoxicity of Targeted Cancer Drugs: Concerns, \u201cThe Cart Before the Horse,\u201d and Lessons from Trastuzumab"],"prefix":"10.1007","volume":"21","author":[{"given":"Pierantonio","family":"Menna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Salvatorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"1121_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.110.165860","volume":"334","author":"G Minotti","year":"2010","unstructured":"Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther. 2010;334:2\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"1121_CR2","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1200\/JCO.2017.76.3920","volume":"36","author":"SH Armenian","year":"2018","unstructured":"Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, et al. Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention. J Clin Oncol. 2018;36:2135\u201344.","journal-title":"J Clin Oncol"},{"key":"1121_CR3","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","volume":"65","author":"GT Armstrong","year":"2015","unstructured":"Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65:2511\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"1121_CR4","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","volume":"25","author":"JR Carver","year":"2007","unstructured":"Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991\u20134008.","journal-title":"J Clin Oncol"},{"key":"1121_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185\u2013229.","journal-title":"Pharmacol Rev"},{"key":"1121_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1021\/tx800002r","volume":"21","author":"P Menna","year":"2008","unstructured":"Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol. 2008;21:978\u201389.","journal-title":"Chem Res Toxicol"},{"key":"1121_CR7","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","volume":"11","author":"P Menna","year":"2012","unstructured":"Menna P, Paz OG, Chello M, et al. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11:S21\u201336.","journal-title":"Expert Opin Drug Saf"},{"key":"1121_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.critrevonc.2018.03.014","volume":"126","author":"HM Babiker","year":"2018","unstructured":"Babiker HM, McBride A, Newton M, Boehmer LM, Drucker AG, Gowan M, et al. Cardiotoxic effects of chemotherapy: a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018;126:186\u2013200.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1121_CR9","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","volume":"133","author":"J Herrmann","year":"2016","unstructured":"Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new--an evolving avenue. Circulation. 2016;133:1272\u201389.","journal-title":"Circulation"},{"key":"1121_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"\u2022 Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457\u201367 A scholar review of new clinical phenotypes of cardiovascular toxicity induced by targeted drugs.","journal-title":"N Engl J Med"},{"key":"1121_CR11","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.115.010484","volume":"132","author":"AM Bellinger","year":"2015","unstructured":"Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. 2015;132:2248\u201358.","journal-title":"Circulation"},{"key":"1121_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000455823","volume":"62","author":"P Menna","year":"2017","unstructured":"Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemother. 2017;62:159\u201368.","journal-title":"Chemother"},{"key":"1121_CR13","doi-asserted-by":"publisher","first-page":"19469","DOI":"10.1074\/jbc.M600399200","volume":"281","author":"K Lemmens","year":"2006","unstructured":"Lemmens K, Segers VF, Demolder M, et al. Role of neuregulin-1\/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem. 2006;281:19469\u201377.","journal-title":"J Biol Chem"},{"key":"1121_CR14","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70:2536\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"1121_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2016.04.015","volume":"104","author":"A Dias","year":"2016","unstructured":"Dias A, Claudino W, Sinha R, Perez CA, Jain D. Human epidermal growth factor antagonists and cardiotoxicity-a short review of the problem and preventative measures. Crit Rev Oncol Hematol. 2016;104:42\u201351.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1121_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ctrv.2011.06.002","volume":"38","author":"E Tagliabue","year":"2012","unstructured":"Tagliabue E, Campiglio M, Pupa SM, M\u00e9nard S, Balsari A. Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev. 2012;38:212\u20137.","journal-title":"Cancer Treat Rev"},{"key":"1121_CR17","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S, Wardley A, Conte PF, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138\u201344.","journal-title":"J Clin Oncol"},{"key":"1121_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"1121_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/378390a0","volume":"378","author":"M Gassmann","year":"1995","unstructured":"Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ERBB4 neuregulin receptor. Nature. 1995;378:39\u201394.","journal-title":"Nature"},{"key":"1121_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/378386a0","volume":"378","author":"D Meyer","year":"1995","unstructured":"Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386\u201390.","journal-title":"Nature"},{"key":"1121_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ERBB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459\u201365.","journal-title":"Nat Med"},{"key":"1121_CR22","doi-asserted-by":"publisher","first-page":"8880","DOI":"10.1073\/pnas.122249299","volume":"99","author":"C Ozcelik","year":"2002","unstructured":"Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, et al. Conditional mutation of the ErbB2 (Her2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99:8880\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1121_CR23","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1074\/jbc.272.9.5783","volume":"272","author":"Z Sheng","year":"1997","unstructured":"Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem. 1997;272:5783\u201391.","journal-title":"J Biol Chem"},{"key":"1121_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/sj.onc.1205100","volume":"21","author":"SL Grant","year":"2002","unstructured":"Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK, et al. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene. 2002;21:460\u201374.","journal-title":"Oncogene"},{"key":"1121_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.addr.2006.05.003","volume":"58","author":"M Pegram","year":"2006","unstructured":"Pegram M, Ngo D. Application and potential limitations of animal models utilized in the development of trastuzumab (HerceptinR): a case study B. Adv Drug Deliv Rev. 2006;58:723\u201334.","journal-title":"Adv Drug Deliv Rev"},{"key":"1121_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1124\/mi.5.3.6","volume":"5","author":"X Peng","year":"2005","unstructured":"Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanisms into preventative medicine. Mol Interv. 2005;5:163\u201371.","journal-title":"Mol Interv"},{"key":"1121_CR27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","volume":"116","author":"K Lemmens","year":"2007","unstructured":"Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116:954\u201360.","journal-title":"Circulation"},{"key":"1121_CR28","first-page":"9","volume":"27","author":"KR Chien","year":"2000","unstructured":"Chien KR. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol. 2000;27:9\u201314.","journal-title":"Semin Oncol"},{"key":"1121_CR29","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","volume":"18","author":"M Pegram","year":"1999","unstructured":"Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241\u201351.","journal-title":"Oncogene"},{"key":"1121_CR30","first-page":"114","volume":"57","author":"G Konecny","year":"1999","unstructured":"Konecny G, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2\/neu overexpression. Breast Cancer Res Treat. 1999;57:114.","journal-title":"Breast Cancer Res Treat"},{"key":"1121_CR31","first-page":"1347","volume":"59","author":"RJ Pietras","year":"1999","unstructured":"Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2\/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347\u201355.","journal-title":"Cancer Res"},{"key":"1121_CR32","first-page":"2825","volume":"58","author":"J Baselga","year":"1998","unstructured":"Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825\u201331.","journal-title":"Cancer Res"},{"key":"1121_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","volume":"14","author":"J Baselga","year":"1996","unstructured":"Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737\u201344.","journal-title":"J Clin Oncol"},{"key":"1121_CR34","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639\u201348.","journal-title":"J Clin Oncol"},{"key":"1121_CR35","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","volume":"16","author":"MD Pegram","year":"1998","unstructured":"Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor enhanced chemosensitivity using recombinant humanized antip185HER2\/neu monoclonal antibody plus cisplatin in patients with HER-2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659\u201371.","journal-title":"J Clin Oncol"},{"key":"1121_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710\u20137.","journal-title":"Ann Intern Med"},{"key":"1121_CR37","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer"},{"key":"1121_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/jpet.117.246140","volume":"364","author":"E Salvatorelli","year":"2018","unstructured":"Salvatorelli E, Menna P, Chello M, Covino E, Minotti G. Low-dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites. J Pharmacol Exp Ther. 2018;364:323\u201331.","journal-title":"J Pharmacol Exp Ther"},{"key":"1121_CR39","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215\u201321.","journal-title":"J Clin Oncol"},{"key":"1121_CR40","first-page":"96","volume":"26","author":"MS Ewer","year":"1999","unstructured":"Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol. 1999;26:96\u2013101.","journal-title":"Semin Oncol"},{"key":"1121_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3816\/CBC.2004.n.033","volume":"5","author":"D Tripathy","year":"2004","unstructured":"Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004;5:293\u20138.","journal-title":"Clin Breast Cancer"},{"key":"1121_CR42","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol. 2007;25:3859\u201365.","journal-title":"J Clin Oncol"},{"key":"1121_CR43","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E Azambuja de","year":"2014","unstructured":"\u2022\u2022 de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01). J Clin Oncol. 2014;32:2159\u201365 Contains remarkably important information on the long-term safety of trastuzumab in survivors of the HERA trial in which trastuzumab was given after (neo)adjuvant anthracycline.","journal-title":"J Clin Oncol"},{"key":"1121_CR44","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372.","journal-title":"N Engl J Med"},{"key":"1121_CR45","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1007\/s10637-012-9811-0","volume":"30","author":"A Gombos","year":"2012","unstructured":"Gombos A, Metzger-Filho O, Dal Lago L, Awada-Hussein A. Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? Investig New Drugs. 2012;30:2433\u201342.","journal-title":"Investig New Drugs"},{"key":"1121_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ctrv.2013.09.002","volume":"40","author":"I K\u00fcmler","year":"2014","unstructured":"K\u00fcmler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014;40:259\u201370.","journal-title":"Cancer Treat Rev"},{"key":"1121_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","volume":"18","author":"SM Swain","year":"2013","unstructured":"Swain SM, Ewer MS, Cort\u00e9s J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18:257\u201364.","journal-title":"Oncologist"},{"key":"1121_CR48","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29:646\u201353.","journal-title":"Ann Oncol"},{"key":"1121_CR49","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1634\/theoncologist.2016-0406","volume":"22","author":"AF Yu","year":"2017","unstructured":"Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, et al. Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist. 2017;22:642\u20137.","journal-title":"Oncologist."},{"key":"1121_CR50","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1078155214527144","volume":"21","author":"JM Baron","year":"2015","unstructured":"Baron JM, Boster BL, Barnett CM. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. J Oncol Pharm Pract. 2015;21:132\u201342.","journal-title":"J Oncol Pharm Pract"},{"key":"1121_CR51","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","volume":"33","author":"IE Krop","year":"2015","unstructured":"Krop IE, Suter TM, Dang CT. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol. 2015;33:1136\u201342.","journal-title":"J Clin Oncol"},{"key":"1121_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","volume":"211","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2018;211:19\u201344.","journal-title":"Recent Results Cancer Res"},{"key":"1121_CR53","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","volume":"83","author":"EA Perez","year":"2008","unstructured":"Perez EA, Koehler M, Byrne J. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679\u201386.","journal-title":"Mayo Clin Proc"},{"key":"1121_CR54","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900\u20132.","journal-title":"J Clin Oncol"},{"key":"1121_CR55","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Wellman R, Feigelson HS. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293\u2013305.","journal-title":"J Natl Cancer Inst"},{"key":"1121_CR56","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1634\/theoncologist.2015-0321","volume":"21","author":"AF Yu","year":"2016","unstructured":"Yu AF, Manrique C, Pun S. Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer. Oncologist. 2016;21:418\u201324.","journal-title":"Oncologist"},{"key":"1121_CR57","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1634\/theoncologist.2015-0449","volume":"21","author":"SR Truong","year":"2016","unstructured":"Truong SR, Barry WT, Moslehi JJ. Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment. Oncologist. 2016;21:666\u201370.","journal-title":"Oncologist"},{"key":"1121_CR58","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.ejca.2015.08.011","volume":"51","author":"E Azambuja de","year":"2015","unstructured":"de Azambuja E, Ameye L, Diaz M. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer. 2015;51:2517\u201324.","journal-title":"Eur J Cancer"},{"key":"1121_CR59","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808\u201315.","journal-title":"J Clin Oncol"},{"key":"1121_CR60","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910\u20136.","journal-title":"J Clin Oncol"},{"key":"1121_CR61","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107\u201315.","journal-title":"J Clin Oncol"},{"key":"1121_CR62","first-page":"2018779736","volume":"23","author":"P Thavendiranathan","year":"2018","unstructured":"\u2022\u2022 Thavendiranathan P, Abdel-Qadir H, Fischer HD, et al. Risk-imaging mismatch in cardiac imaging practices for women receiving systemic therapy for early-stage breast cancer: a population-based cohort study. J Clin Oncol. 2018;23:2018779736 Important metanalysis showing that baseline cardiac imaging is driven primarily by chemotherapy regimen rather than heart failure risk. It may help to reconcile conflicting reports on the cardiac safety or toxicity of trastuzumab and other agents in cancer patients.","journal-title":"J Clin Oncol"},{"key":"1121_CR63","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/21645515.2015.1125056","volume":"12","author":"G Riccio","year":"2016","unstructured":"Riccio G, Coppola C, Piscopo G, Capasso I, Maurea C, Esposito E, et al. Trastuzumab and target-therapy side effects: is still valid to differentiate anthracycline type I from type II cardiomyopathies? Hum Vaccin Immunother. 2016;12:1124\u201331.","journal-title":"Hum Vaccin Immunother"},{"key":"1121_CR64","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","volume":"13","author":"AU Buzdar","year":"2007","unstructured":"Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228\u201333.","journal-title":"Clin Cancer Res"},{"key":"1121_CR65","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","volume":"50","author":"MS Ewer","year":"2014","unstructured":"Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 2014;50:2162\u201370.","journal-title":"Eur J Cancer"},{"key":"1121_CR66","volume-title":"Cancer and the Heart","author":"E Salvatorelli","year":"2018","unstructured":"Salvatorelli E, Menna P, Minotti G. Pharmacology of cardio-oncology. In: Ewer MS, Yeh ET, editors. Cancer and the Heart. Shelton: People\u2019s Medical Publishing House, CT; 2018. (in press)."},{"key":"1121_CR67","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/14740338.2017.1354987","volume":"16","author":"P Menna","year":"2017","unstructured":"Menna P, Salvatorelli E, Minotti G. Cancer drugs and QT prolongation: weighing risk against benefit. Expert Opin on Drug Saf. 2017;16:1099\u2013102.","journal-title":"Expert Opin on Drug Saf"},{"key":"1121_CR68","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.","journal-title":"Lancet."}],"updated-by":[{"DOI":"10.1007\/s11886-019-1131-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000}}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1121-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1121-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1121-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:09:38Z","timestamp":1584403778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1121-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1121-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11886-019-1131-y","asserted-by":"object"}]},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"18 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication, there were two errors in Fig.\u00a02. \u201cAnhracyline\u201d should be \u201cAnthracycline\u201d and \u201ctargetd\u201d should be \u201ctargeted.\u201d The original article has been corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Pierantonio Menna, Giorgio Minotti, and Emanuela Salvatorelli declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"33"}}